Human monoclonal antibody development
Upcoming SlideShare
Loading in...5
×
 

Human monoclonal antibody development

on

  • 4,868 views

 

Statistics

Views

Total Views
4,868
Views on SlideShare
4,813
Embed Views
55

Actions

Likes
0
Downloads
80
Comments
0

2 Embeds 55

http://www.scoop.it 54
http://translate.googleusercontent.com 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Human monoclonal antibody development Human monoclonal antibody development Presentation Transcript

    • Janos Luka, Ph.D. Scientific DirectorBioworld Consulting Laboratories, LLC http://www.bioworldantibodies.com 1
    •  The current methods of antibody development are mainly hybridoma based method using mice, and phage display method Some companies also use the EBV transformation method which have several disadvantages including loss of specific B-cells and IgM type of antibody response http://www.bioworldantibodies.com 2
    • Unique proprietary method to capture andimmortalize natural human antibody producing cellsfor in vitro production of antigen specific humanantibodies.  it does not require isolation and purification of B-cells therefore no loss of antigen specific B-cells occurs, which is generally associated with other methods.  it produces natural human antibodies, which has been innately produced by the immune system. It can be easily characterized for specific therapies and epitope mapped without recombinant technology. http://www.bioworldantibodies.com 3
    •  antibodies against multiple epitopes can be isolated, and combined as multiclonal or polyclonal mixture which might be more effective than a single monoclonal antibody for clinical use once the donor blood has been obtained, it will take only 6-8 weeks to obtain the monoclonal antibody producing clones compared to traditional methods which might take up to several years. if blood donors with previous exposure to antigen of the interest cannot be found, in vitro immunization can be done to produce human antibodies http://www.bioworldantibodies.com 4
    •  The technology uses a proprietary method to generate an antigen presentation system, which emulates the natural presentation of antigens by the immune system. BCL has initiated proof of principle studies to generate antibodies against specific tumor associated antigens by means of in vitro immunization using on purified antigens and peptides. http://www.bioworldantibodies.com 5
    • http://www.bioworldantibodies.com 6
    •  For generating specific antibody producing cells, first we examine by ELISA whether aimed antibodies are present in the serum of the donors. this screening is completed in one day, and reveals which donors are suitable for human antibody development. In the next step, the antibody producing cells are immortalized from the donors where the antibodies have been confirmed to be present. http://www.bioworldantibodies.com 7
    •  Transformed lymphocytes are dropped on 50,000 wells micro-array (coated with specific antigen) and incubated for several hours. The specific antibody producing single cells are identified by fluorescence. The cells that are secreting antibodies to the antigen are isolated with a micro- manipulator, then expanded. The expanded cells, which now produce specific antibodies can be further characterized before transferring the IgG genes for other cells (CHO) for large scale production http://www.bioworldantibodies.com 8
    •  Not affected by patents associated with other technologies Rapid progress from target identification to clinical development using epitope specific antibodies Clones can be selected targeting different epitopes on the same antigen Native human antibodies, therefore unlikely to be immunogenic or induce adverse effects in patients, which generally a problem with humanized antibodies. http://www.bioworldantibodies.com 9
    •  Bioworld Consulting Laboratories antibodies are fully human antibodies, and of high affinity. Due to the high affinity and selectivity, it is expected that our antibodies will be effective at lower dosages, resulting in reduction of cost during large scale production. Each antibody developed has unique amino- acid sequence therefore substance patent can be approved. http://www.bioworldantibodies.com 10